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Abstract 
Pineal Parenchymal tumour with intermediate differentiation (PPTID) is a rare disorder, first classified by World Health 
Organisation in 2000. There are very few published data available and optimal management is yet to be determined. 
Management has varied from surgery alone to craniospinal radiotherapy with or without chemotherapy. We present 
our experience of PPTID treated with radiotherapy alone. We conducted a retrospective review of patients who were 
diagnosed with PPTID and treated with radiation therapy at our institute from 2010 onwards. Between January 2010 
to January 2013, 5 patients of PPTID were treated at our institute. Median age is 44 (range 24–62). All patients had 
preoperative MRI scan of brain and spine. Imaging did not identify any spinal dissemination. None of the patients 
underwent a gross total resection, due to the tumour location and technical difficulties. All patients were treated with 
external beam radiation therapy to primary lesion only with a dose of 54 Gy in 30 fractions after surgery. 4 patients 
had good partial response and the remaining 1 has stable disease. After 21.4 months of median follow up no disease 
recurrence was reported. So far there is no evidence of cerebral white matter abnormalities on MRI scan or neurocog-
nitive disorders. Our experience indicated that localised radiation therapy could be an effective treatment strategy for 
PPTID, considering the long natural course of the disease and the late adverse effects of intensive treatment.
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Background
Tumours arising in the pineal area are heterogeneous 
in nature (British Neuro-Oncology Society/NCAT Rare 
Tumour Guidelines 2011). Pineal parenchymal tumours 
are rare, accounting for  <0.3  % of all primary central 
nervous system tumours.  Among all Pineal tumours 
PPTID is a relatively rare group with considerable mor-
phological variation. PPTID is a new addition to the 
WHO classification of central nervous system tumours 
(Louis et al. 2007) and may account for up to 20 % of pin-
eal tumours. The WHO classification of central nervous 
system tumours (2007 revision) has subdivided pineal 
tumours into 4 grades: Pineocytoma (PC) grade 1 and 
Pineoblastoma (PB) grade IV (Jouvet et al. 2000); Papil-
lary tumor of the pineal region and pineal parenchymal 
tumor of intermediate differentiation (PPTID) are con-
sidered as intermediate grade and both can be subdivided 
into grade 2 or 3 (2).
There is no particular sex predominance and they are 
more common in middle aged patients (Sato and Kubota 
2009). The optimal management for PPTIDs has yet to 
be determined. It is a relatively new disease entity and 
very few published data are available. At one end of the 
spectrum, patients treated with surgery alone, exhib-
ited long term survival. At the other extreme, studies 
describe PPTIDs as tumours with seeding potential and 
recommend postoperative treatment in a manner simi-
lar to that for pineoblastomas (Schild et  al. 1993). This 
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raises an important question as to what should be the 
ideal treatment for PPTID. As it is an intermediate grade 
lying between pinocytoma and pinoblastoma do we need 
to adopt an intermediate treatment strategy? The aim of 
this study was to retrospectively analyse the role of local-
ised radiation therapy for PPTID patients treated at our 
institution.
Methods
We conducted a retrospective review of patients who 
were diagnosed with PPTID and treated with radiation 
therapy at our institution from January 2010 onwards. 
The patients were identified from an in-house data base. 
Clinical data, pathological results, imaging [magnetic 
resonance imaging (MRI)], initial treatment, resection 
status, details of radiation therapy, initial response to 
treatment, recurrence pattern and late adverse toxici-
ties, were collected. The study was ethically approved by 
Department of Oncology and Neurosurgery. All patients 
were contacted and consent was obtained.
‘Gross total resection’ was defined as no evidence of 
contrast-enhancing tumour on postoperative images; 
‘R2-resection’ was any surgical tumour resection less 
than gross total resection; and ‘biopsy only’ was no surgi-
cal tumour resection due to inoperability, with a biopsy 
performed to determine tumour histology (Stoiber et al. 
2010).
The response criteria were described as follows: com-
plete response (CR), disappearance of tumour; partial 
response (PR), >50  % decrease in tumour size; progres-
sive disease, >25 % increase in tumour size or any appear-
ance of new sites; stable disease (SD), all other situations.
The late effect of the treatment were assessed by 
appearance of cerebral white matter abnormalities in 
MRI after treatment and grading system of Radiation 
Therapy Oncology Group (RTOG) and common termi-
nology criteria for adverse events (CTCAE), version 4.0. 
The classification according to neurocognitive disorders 
are as follows: RTOG (neurological/cortical) grade 1, 
mild somnolence or agitation; grade 2, moderate somno-
lence or agitation; grade 3, severe somnolence, agitation, 
confusion, disorientation or hallucinations; and grade 4, 
coma, seizures and toxic paralysis; and CTCAE (cognitive 
disturbance) grade 1, mild cognitive disability, not inter-
fering with work/school/life performance, specialized 
educational services/devices not indicated; grade 2, mod-
erate cognitive disability, interfering with work/school/
life performance but capable of independent living, spe-
cialized resources indicated on a part-time basis; grade 3, 
severe cognitive disability, with significant impairment of 
work/school/life performance.
Patient demographics
Between January 2010 and January 2013, 5 patients with 
PPTID were treated at our institution. Table  1 summa-
rizes the patient and tumour characteristics, and the 
treatment received. Median age was 44 (range 24–62) 
and 60 % are female. All patients had preoperative MRI 
scan of brain and spine. Imaging did not identify any 
spinal dissemination. No patient had routine lumbar 
puncture preoperatively. Two patients were pathologi-
cally classified as WHO grade III and 3 were grade II. 
The grade of the disease was determined by the mitotic 
count, presence of neurofilament staining and the prolif-
eration index (Figs. 1, 2).   
Histopathology
Pineal parenchymal tumours of intermediate differentia-
tion are graded as lying between Pineocytomas (WHO I) 
and Pineoblastomas (WHO IV). Pineocytomas are well 
differentiated with small, uniform, mature cells and vir-
tually lack mitoses. They have numerous, large pineo-
cytomatous rosettes. Pineoblastomas are highly cellular 
tumours with frequent mitotic figures, irregular nuclei, 
large nucleus to cytoplasmic ratio; they form pattern-less 
sheets, with necrotic areas being common, and rosettes 
are rare (Louis et al. 2007). Pineal parenchymal tumours 
of intermediate differentiation are still a grey area but 
generally have moderate cellularity, mild to moder-
ate nuclear atypia and low to moderate mitotic activity. 
Necrosis and endothelial proliferation are absent in con-
trast to pineoblastomas (Mena et al. 2000).
The presence of necrosis, mitotic rate and immuno-
histochemical expression of neurofilament protein are 
Table 1 Patients and tumour characteristics









1 F 37 No Biopsy only 3 + 10–15 PR No
2 F 61 No R2 2 ++ 0 SD No
3 F 56 No R2 2 +++ 3 PR No
4 M 24 No R2 3 ± 10–12 PR No
5 M 62 No R2 2 +++ 5 PR No
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used to classify PPTIDs as grade II or III pathologically 
(Sato and Kubota 2009). Jouvet et al. defined that grade 2 
tumour has <6 mitoses and strongly immunopositive for 
neurofilaments and grade 3 will have,  >6 mitoses or  <6 
mitoses, but without strong immunostaining for neuro-
filaments (Jouvet et al. 2000).
Tsumanuma et  al. described MIB-1 index as sig-
nificantly higher in PB after analysing 13 cases of Pin-
eal Parenchymal tumours (Tsumanuma et  al. 1999). 
A clinicopathologic study of PPTID by Ito et  al. found 
MIB-1 level correlates with WHO grade (Ito et al. 2014).
Figures 1 (grade II) and 2 (grade III) describe the his-
topathological characteristics of two of our patients. In 
these two cases, the tumours are more cellular than in 
pineocytoma and the cells have more atypical nuclei but 
not atypical enough to be labelled pineoblastoma. Both 
cases were Synaptophysin positive, which support a 
tumour of pineal origin.
Fig. 1 a Malignant pineocytes with stippled nuclear chromatin and moderately eosinophilic cytoplasm arranged around a Homer-Wright rosette.         
b MIB-1 demonstrating a low proliferative index. c Frozen section image: tumour appear more closely packed with denser chromatin. Apoptotic 
bodies are visible (arrow). d Synaptophysin immunochemistry showing granular cytoplasomic positivity. e Strong neurofilament staining on all cells
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Mitotic figures are seen (more easily identified in the 
grade III case) which is uncharacteristic of a pineocy-
toma but the low MIB-1 proliferation index would weigh 
against a pineoblastoma. The Fig.  1 also shows very 
strong positivity towards neurofilament staining.
Radiological diagnosis
Radiologically, PPTID is difficult to differentiate from 
other pineal tumours (Osborn et al. 2012; Fang and Mey-
ers 2013). Peripheral displacement of pineal calcification 
may help to confirm a tumour of pineal parenchymal ori-
gin (Osborn et al. 2012). Both pineoblastoma and PPTID 
may show local invasion, but pineoblastoma is typically 
seen in children. PPID is distinguished from pinocytoma 
by large size and focal invasion of adjacent structures. 
Hemorrhage and cysts are common (Fig.  3). Therefore, 
it has been suggested that the Radiologist should sug-
gest PPTID if a locally invasive enhancing pineal paren-
chymal tumour is seen in an adult patient. However, this 
finding was only seen in one of our patients, although it is 
interesting that this tumour also demonstrated diffusion 
restriction which can be a marker of cellular and more 
anaplastic tumours (Cha 2006). Magnetic resonance 
spectroscopy in one of our patients showed changes con-
sistent with tumour, but not specific for PPTID (Fig. 4).
Treatment
Four patients had an R2-resection due to tumour loca-
tion and invasion toward the surrounding eloquent areas. 
One patient had biopsy only. No post operative complica-
tion was documented. All the patients were treated with 
external beam radiation therapy post operatively.
Radiotherapy
All patients were treated in supine position and immo-
bilised with Beam Directed Shell (BDS). Planning CT 
scan was fused with post operative MRI scan to deline-
ate tumour volume. Gross Tumour Volume (GTV) was 
Fig. 2 a Malignant pineocytes exhibit increased nuclear pleomorphism. A mitotic figure is present (arrow). b MIB-1 demonstrating higher prolifera-
tive index. c Weak, patchy neurofilament staining positivity most cells are negative
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defined as all visible tumour on post operative MRI scan 
and planning CT scan. Clinical Target Volume (CTV) 
was created by adding a 15 mm margin to the GTV. CTV 
to Planning Treatment Volume (PTV) margin was 5 mm. 
The prescribed dose was 54 Gy in 30 fractions (1.8 Gy per 
fraction). The radiation was delivered by a linear acceler-
ator with energy of 6 MV. Patients were assessed for side 
effects and compliance with treatment on a weekly basis 
during therapy. Patients underwent 3 monthly follow-up 
MRI scans in the first year and then 6 monthly thereafter.
Outcome
Result
No patients developed recurrence after 21.4  months of 
median follow up (range 7–43  months). Four patients 
achieved PR (Fig.  5) and 1 patient had SD. All patients 
were alive at the end of the observation period.
Toxicity
All patients had an uneventful post-operative recovery. 
No serious intracranial bleeding was recorded in the 
perioperative period. No patients exhibited evidence of 
neurocognitive disorders, neither was there any evidence 
of cerebral white matter abnormalities on follow up MRI 
scans. So far no endocrine deficiency or visual impair-
ment has been documented.
Discussion
There is limited evidence available to guide the manage-
ment of PPTID and currently no general consensus exists 
concerning treatment. Our study may add important evi-
dence regarding viable treatment outcomes with local-
ised field radiation therapy in PPTID.
Radiotherapy
PPTID is radiosensitive tumour (Anan et al. 2006). Rick-
ert et al. reported that PPTIDs resembled PB genomically 
but PC prognostically, which raised an important ques-
tion of whether PPTIDs should be treated in a similar 
fashion to PC or PB (Rickert et al. 2001).
The role of radiotherapy has been highlighted in vari-
ous studies but the extent of radiation therapy in PPTID 
has yet to be determined. The role of craniospinal and 
whole-ventricular irradiation for patients with PPTID 
remains controversial.  A single institutional study of 
six patients with PPTID by Ito et  al. showed five cases 
obtained almost complete response to radiotherapy 
but only 2 patients had localised radiotherapy (Ito et al. 
2014). Lutterbach et  al. pointed out that survival out-
come is strongly related with CSF dissemination in adult 
pineal parenchymal tumours and spinal control was more 
successful in patients with pineal parenchymal tumours 
of intermediate differentiation (Lutterbach et  al. 2002). 
Interestingly a clinicopathological study of 76 patients 
with pineal tumour revealed extent of radiotherapy had 
no clear influence on survival (Fauchon et  al. 2000). 
Stoiber et  al. reported local radiotherapy seems to be 
effective in patients with PC and some PPTIDs after ana-
lysing patients retrospectively (Stoiber et al. 2010).
Ito et  al. has raised questions whether radiotherapy 
could be omitted in grade 2 PPTID? (Ito et al. 2014). We 
felt postoperative RT is necessary for all cases as com-
plete resection is extremely difficult due to the invasive 
nature of the disease.
The association between radiation dose and survival 
outcome is also a matter of debate. A study by Schild et al. 
(1996) of 30 patients showed an link between the radia-
tion dose and survival time in patients with pineal paren-
chymal tumours. In that study patients who received 
doses >50 Gy had a significantly improved 3-year survival 
rate compared to those who received lower doses (94 vs 
56 %, respectively) .In our study all patients were treated 
with 54 Gy to primary site with good outcome which is 
consistent with Schild’s report. Table 2 summarises vari-
ous published studies which used radiotherapy in PPTID.
Interestingly all patients in our cohort were treated 
with localised radiotherapy with no relapses to date. 
Craniospinal radiation would be a logical approach 
for patients with spinal dissemination. Our experience 
raised an important question should we exclude spinal 
Fig. 3 CT scan a shows homogenous mass in pineal region 
with peripheral calcification and obstructive hydrocephalus. b 
T2-weighted MRI shows multiple small cysts within the mass and 
probable invasion of left thalamus, c confirmed on T1-weighted scan 
after intravenous Gadolinium. d Diffusion-weighted scan (b = 1000) 
shows small area of diffusion restriction anteriorly within the tumour 
(confirmed on Apparent Diffusion Coefficient map), close to the left 
thalamus
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radiation for patient who do not have spinal involvement 
radiologically?
Chemotherapy
The role of chemotherapy in PPTID patients remains 
controversial. A retrospective review of PPTID patients 
by Tsubasa et al. showed four out of five patients received 
six courses of combination chemotherapy with vincris-
tine (0.6  mg/m2), nimustine (60  mg/m2), carboplatin 
(110 mg/m2) and interferon β (3 × 106 IU) (Tsubasa et al. 
2014). One patient, who did not receive chemotherapy, 
developed spinal seeding after treatment. Another study 
utilised combination chemotherapy with cisplatin and 
vinblastine as systemic treatment of pineal parenchymal 
cell tumours (Kurisaka et al. 1998). Li et al. demonstrated 
the presence of a mutation of epidermal growth fac-
tor receptor (in-frame deletion of exons 2–7) in PPTID 
tumours (Li et al. 2010). This study indicated the proba-
ble benefit of targeted agents in PPTID. Interestingly our 
study would call into question the routine use of chemo-
therapy in PPTID patients with localised disease given 
the excellent outcome to date.
Due to long survival outcome of PPTID patients, late 
adverse effects are an important consideration. Wide 
field irradiation with the addition of systemic therapy 
definitely increases the long term side effects of treat-
ment. The study by Tsubasa showed two patients who 
received craniospinal irradiation exhibited severe cogni-
tive impairment 4–6 years after radiation therapy (Tsub-
asa et  al. 2014). Some data suggested injury to neural 
progenitor cells plays an important role in treatment-
related neurocognitive toxicity (Limoli et al. 2004).
Chemotherapy also enhances neurocognitive toxic-
ity due to the different sensitivity of normal neural stem 
Fig. 4 T1-weighted MRI scan after intravenous Gadolinium a shows patchy enhancement of mass in pineal region and obstructive hydrocephalus. 
No evidence of local invasion. b Single-voxel MR spectroscopy (TE = 144) shows moderate elevation of Choline, reduction in NAA and inverted 
lactate doublet
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cells  (Gong et  al. 2011). Targeted agents, including epi-
dermal growth factor receptor tyrosine kinase inhibi-
tors and proteasome inhibitors, were also found to be 
potentially more neurotoxic compared to conventional 
chemotherapeutic agents (Bota et  al. 2013). Radiation 
contributes to increased chemotherapeutic neurocog-
nitive toxicity due to blood brain barrier damage which 
essentially increases the penetration of chemotherapy 
(Brown et al. 2007).
There are some limitations to our study. Firstly, It is a 
retrospective study with a small number of patients and 
consequently care must be taken in generalising our 
results to a larger population. Secondly, follow-up is 
short at under 2 years, particularly if long-term toxicity 
is to be reliably estimated. In addition we could be criti-
cised for failing to perform routine pre-operative CSF 
(cerebro spinal fluid) analysis to exclude the presence of 
CSF seeding particularly as we are advocating a localised 
radiotherapy approach to treatment.
Conclusion
Our experience indicates that localised radiation therapy 
could be an effective treatment strategy for PPTID, con-
sidering the long natural course of the disease and the 
late adverse effects of intensive treatment. We did not 
use spinal radiation and systemic therapy in an attempt 
to minimise treatment related toxicities and none of our 
patients has experienced disease recurrence to date. Tak-
ing into account the rarity of this disease, prospective 
multi-institutional studies could be extremely difficult. 
One realistic option would be to consider a registry based 
study.
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